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ABSTRACT
Intermittent parathyroid hormone (PTH) treatment is a potent bone anabolic principle that suppresses expression of the bone formation
inhibitorSost.WeaddressedtherelevanceofSostsuppressionforPTH-inducedboneanabolisminvivousingmicewithalteredSostgene
dosage. Six-month-old Sost overexpressing and 2-month-old Sost deficient male mice and their wild-type littermates were subjected to
daily injections of 100mg/kg PTH(1–34) or vehicle for a 2-month period. A follow-up study was performed in Sost deficient mice using 40
and 80mg/kg PTH(1–34). Animals were sacrificed 4 hours after the final PTH administration and Sost expression in long bone diaphyses
wasdeterminedbyqPCR.BonechangeswereanalyzedinvivointhedistalfemurmetaphysisbypQCTandexvivointhetibiaandlumbar
spine by DXA. Detailed ex vivo analyses of the femur were performed by pQCT, mCT, and histomorphometry. Overexpression of Sost
resulted in osteopenia and Sost deletion in high bone mass. As shown before, PTH suppressed Sost in wild-type mice. PTH treatment
induced substantial increases in bone mineral density, content, and cortical thickness and in aging wild-type mice also led to cancellous
bone gain owing to amplified bone formation rates. PTH-induced bone gain was blunted at all doses and skeletal sites in Sost
overexpressing and deficient mice owing to attenuated bone formation rates, whereas bone resorption was not different from that in
PTH-treated wild-type controls. These data suggest that suppression of the bone formation inhibitor Sost by intermittent PTH treatment
contributes to PTH bone anabolism.  2010 American Society for Bone and Mineral Research.
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Introduction
O
steoporosis is a systemic skeletal disorder characterized by
low bone mass and microarchitectural deterioration of
bone tissue with a consequent increase in bone fragility and
susceptibility to fracture.
(1) It is characterized by a disturbed
remodeling balance of bone resorbing osteoclasts and bone
forming osteoblasts, resulting in a net decrease in bone mineral
density (BMD). Most osteoporosis therapies are based on
inhibition of bone catabolic osteoclast activity and hence can
merely prevent further bone loss. The only clinically approved
bone anabolic therapy, which can restore bone, is intermittent
parathyroid hormone (PTH) treatment by daily injection.
(2,3)
While it is an established bone forming principle, the underlying
molecular mechanisms are only partially understood. PTH affects
cells of the mesenchymal osteoblast lineage by signaling
through the G-protein-coupled type 1 PTH/PTH-related peptide
receptor (PTH1R).
(4) It has been shown to increase osteoblast
number by promoting osteoblastic precursor proliferation
(5,6)
and reactivating quiescent bone lining cells,
(7) as well as by
stimulating osteoblast survival.
(8,9) In addition, intermittent PTH
treatment enhances osteoblast differentiation and activity.
(10)
Finally, emerging evidence suggests a putative role for
osteocytes in PTH-induced bone anabolism.
(11–13)
Osteocytes represent the majority of all bone cells. They are
terminally differentiated cells of the osteoblast lineage
embedded within the mineralized bone matrix.
(14) They are
interconnected with each other and with osteoblasts and lining
cells on the bone surface via dendritic processes, forming a
communication network throughout the bone matrix and to the
bone surface that seems ideally suited for sensing and
responding to the needs of the skeleton. Osteocytes express
not only PTH1R
(15,16) but also express Sost, a potent bone-
formation inhibitor,
(17,18) suggesting that they might play an
important function in control of bone homeostasis. We and
others recently found that PTH signaling suppresses the
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178expression of Sost at the transcriptional level in a direct
manner.
(11,12) Consistent with Sost encoding sclerostin, a
secreted glycoprotein inhibiting bone formation, transgenic
mice overexpressing human SOST exhibit a low bone mass
phenotype.
(19,20) Conversely, constitutive Sost knockout (KO)
mice lacking Sost expression display a high bone mass
phenotype and increased bone strength.
(21) Moreover, patients
afflicted by sclerosteosis (MIM 269500)
(22,23) or van Buchem
disease (MIM239100)
(24,25) displaylifelongboneovergrowth and
a high bone mass phenotype with strongly increased bone
mineral mass, density, and strength owing to loss of SOST
expression.
The role of PTH signaling in osteocytes for the regulation of
bone homeostasis was addressed recently by overexpressing a
constitutively active PTH1R variant selectively in osteocytes.
(13)
Constitutively active PTH1R transgenic mice display increased
bone mass and turnover and a concomitant reduction in Sost
expression. These findings, together with the earlier observation
that Sost is suppressed by PTH signaling,
(11,12) suggest that
osteocytes might contribute to PTH-induced bone anabolism
and that suppression of Sost may play a role in the bone anabolic
activity of intermittent PTH treatment.
To address the relevance of Sost suppression for PTH-induced
bone gain, we employed genetically engineered mouse models
with altered Sost expression levels. We subjected SOST
transgenic (SOST Tg) mice overexpressing human SOST and
homozygous Sost KO mice lacking endogenous mouse Sost to 2
months of intermittent bone anabolic PTH treatment. We
hypothesized that the contribution of suppression of Sost for
PTH-induced bone anabolism might be reduced under condi-
tions of increased Sost gene dosage. Likewise, we reasoned that
if PTH-induced suppression of Sost contributes to PTH-
dependent bone anabolism in vivo, the bone anabolic response
induced by intermittent PTH treatment should be attenuated in
homozygous Sost KO mice, which lack Sost constitutively.
Alternatively, if transient suppression of Sost is dispensable for
PTH-induced bone anabolism in vivo, we expected to detect
additive effects of Sost deficiency and intermittent PTH
treatment. Here we report that PTH-induced bone anabolism
is blunted in Sost overexpressing and deficient mice, suggesting




The generation of SOST bacterial artificial chromosome (BAC)
transgenic (SOST Tg) mice was described previously.
(20) SOST Tg
miceweremaintainedonamixedFVB-C57BL/6background.Sost
KO mice with a targeted disruption of the Sost coding region
were licensed from Deltagen, Inc. (San Mateo, CA, USA). Briefly,
targeted ES cells derived from the 129/OlaHsd mouse substrain
were used to generate chimeric mice, which were bred with
C57BL/6 mice. Heterozygous Sost KO offspring were backcrossed
for 4 generations to C57BL/6 mice and then interbred to
generate homozygous Sost mutant mice. All mice were kept in
cages under standard laboratory conditions with constant
temperature of 258C and a 12-12-hour light-dark cycle. Mice
were fed on a standard rodent diet (3302, Provimi Kliba SA,
Switzerland) with water ad libitum. Protocols, handling, and care
of the mice conformed to the Swiss federal law for animal
protection under the control of the Basel-Stadt Cantonal
Veterinary Office, Switzerland.
Systemic intermittent PTH(1–34) treatment
Six-month-old SOST Tg and 1.5-month-old [or 2-month-old in
case of the hPTH(1–34) dosing experiment] Sost KO male mice
and their wild-type male littermates were assigned to treatment
groups (n¼17 to 18 per group for the SOST Tg experiment, n¼5
to 10 per group for Sost KO experiments) according to cross-
sectionaltotalBMDintheproximaltibiametaphysisasmeasured
by peripheral quantitative computed tomography (pQCT) as first
rank and body weight as second rank such that comparable
group means and standard variations between groups desig-
nated to receive vehicle or PTH treatment were achieved at
baseline in order to minimize experimental artifacts. All animals
received daily subcutaneous injections on 6 (for the SOST Tg
experiment) or 5 days per week (for Sost KO experiments) of
vehicle (0.1% bovine serum albumin in phosphate-buffered
saline, pH 7.4; Invitrogen, Karlsruhe, Germany) or 100mg/kg
human PTH(1–34) peptide [hPTH(1–34); Bachem, Bubendorf,
Switzerland] with the exception of the hPTH(1–34) dosing
experiment, in which treatment groups received 40 or 80mg/kg
hPTH(1–34). After 9 weeks of treatment, mice were sacrificed
4 hours after the final PTH injection by isoflurane or CO2-air
inhalation followed by exsanguination.
RNA extraction and quantitative real time PCR (qPCR)
expression analyses
Total RNA was isolated from cortical bone of tibial or femoral
diaphyses using TRIzol (Invitrogen, Karlsruhe, Germany) and
RNeasy Mini (Qiagen, Hilden, Germany), as described pre-
viously,
(11) and reverse-transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Rotkreuz, Switzerland) according to the manufacturer’s recom-
mendations. Gene expression analyses were performed with an
ABI Prism 7900HT sequence detection system (Applied Biosys-
tems) using TaqMan Universal PCR Master Mix mouse or human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) TaqMan
assay reagents for normalization and TaqMan probes for mouse
and human Sost/SOST according to the manufacturer’s instruc-
tions (Applied Biosystems).
Ex vivo dual-energy X-ray absorptiometry (DXA) analyses
The left tibia and lumbar vertebrae L1–4 were dissected, fixed for
24 hours in 4% phosphate-buffered paraformaldehyde, and
stored in 70% ethanol. Tibial and lumbar spine BMD was
measured in 70% ethanol for soft tissue calibration with a
Hologic QDR-1000 instrument. A collimator with 0.9-cm-
diameter aperture and an ultrahigh-resolution mode (line
spacing 0.254mm, resolution 0.127mm) were employed.
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(pQCT) analyses
Cross-sectional BMD, bone mineral content (BMC), and cortical
thickness were evaluated in the left proximal tibia and distal
femur metaphysis using an adapted Stratec-Norland XCT-2000
fitted with an Oxford (Oxford, UK) 50mm X-ray tube (GTA6505M/
LA)andacollimatorof0.5mmdiameter.Thefollowingsetupwas
chosen for the measurements: voxel size 0.07mm, scan speed
scout view 10mm/s, final scan 5mm/s, 1 block, contour mode 1,
peelmode 2,and cortical andinner threshold350mg/cm
3. Forin
vivo measurements, animals were placed in the lateral position
under inhalation narcosis (isoflurane 2.5%), and the left leg was
stretched and fixed. For ex vivo analyses of the femur, six
consecutiveslicesspacedequallyalongtheentirefemorallength
were measured, and slices 1 to 5 were evaluated, with slice 1
being the most distal corresponding to the distal femur
metaphysis.
Micro-computed tomographic (mCT) analyses
Cancellous bone structure was evaluated ex vivo in the distal
femur metaphysis using a Scanco vivaCT40 (voxel size 10.5mm,
high resolution, 50 slices, threshold 275; Scanco Medical AG,
Bruttisellen, Switzerland).
Tissue processing and bone histomorphometric
analyses
All mice received fluorochrome markers by subcutaneous
injection 10 days (alizarin complexone, 20mg/kg; Merck, Zug,
Switzerland) and 3 days prior to necropsy (calcein, 30mg/kg;
Fluka, Buchs, Switzerland) to evaluate bone formation dynamics.
The left femur was fixed for 24 hours in 4% phosphate-buffered
paraformaldehyde, dehydrated and defattened at 48C, and
embedded in methyl methacrylate resin. Per animal, a set of
5mm nonconsecutive longitudinal sections was cut in the frontal
midbody plane (Leica RM2155 microtome, Leica Microsystems,
Heerbrugg, Switzerland). Fluorochrome-marker-based dynamic
bone parameters were determined using a Leica DM microscope
fitted withaSony DXC-950P camera and adapted Quantimet 600
software (Leica Microsystems). Microscopic images of the
specimen were digitized and evaluated semiautomatically on
screen (200 magnification) as described previously.
(26) Bone
surface, single- and double-labeled bone surface, and interlabel
width were measured in the cancellous bone compartment of
the distal femur metaphysis. Mineralizing surface [MS/
BS¼(dLSþsLS/2)/BS (%)] and mineral apposition rate [MAR
(mm/day), corrected for section obliquity] were calculated, and
the daily bone formation rate [BFR/BS (mm/d)] was derived.
Osteoclast number was determined on 5mm femoral microtome
sections stained for tartrate-resistant acid phosphatase (TRAP)
activity. Bone histomorphometric nomenclature was applied as
recommended by Parfitt and colleagues.
(27)
Statistical analysis
All data shown represent mean standard error of the mean
(SEM). Statistical analyses were performed using Student’s t tests
(two-tailed)orone-wayanalysisofvariance(ANOVA).Thelevelof
significance is designated as follows:
 ,Xp<.05 and
  ,XXp<.01.
Unpaired Student’s t tests were used for PTH- versus vehicle-
treated mice of the same genotype (
 ,
  ) or for transgenic versus




Skeletal parameters of SOST Tg Tg mice and SOST
expression
Consistent with SOST encoding a bone formation inhibitor and
previously reported findings,
(20) SOST Tg male mice expressing
wild-type human SOST from a bacterial artificial chromosome
(BAC) transgene under control of the human genomic context
develop osteopenia with increasing age (Fig. 1A, B). Cross-
sectional total BMD in the distal femur metaphysis was
significantly lower in SOST Tg relative to wild-type littermate
males, as evaluated in vivo by pQCT analyses during late-stage
skeletal growth (3 months of age) and during skeletal aging
(see Fig. 1A). Likewise, femoral cross-sectional cortical thickness
was significantly decreased in aging SOST Tg mice compared
with wild-type littermates (see Fig. 1B).
We then subjected 6-month-old SOST Tg mice and their
wild-type littermate males to 2 months of intermittent PTH
treatment using daily injections of 100mg/kg hPTH(1–34)
peptide. 4 hours after the final hPTH(1–34) application, the
mice were sacrificed, and endogenous and transgenic Sost
Fig. 1. SOST overexpression results in osteopenia, and SOST is sup-
pressed by PTH. Cross-sectional total BMD (A) and cortical thickness
(B) in the distal femur metaphysis were evaluated by monthly in vivo
pQCT measurements of skeletally mature to aging wild-type (white data
points) and SOST Tg (filled data points) littermate male mice. Relative
expression of endogenous mouse Sost (C) and transgenic human SOST
(D) in cortical bone of the tibia diaphysis normalized to GAPDH with the
corresponding DCt values indicated below the bars was determined by
qPCR 4 hoursfollowingthefinal PTH(hatched bars) or vehicle(whitebars)
injection after 2 months of intermittent treatment with 100mg/kg
hPTH(1–34). Data represent means SEM. n.a.¼not applicable.
 p<
.05,
  p<.01;unpairedStudent’st testsforSOSTTgversuswild-type(A,B)
or PTH- versus vehicle-treated mice of the same genotype (C, D).
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reports,
(11,12) endogenous Sost expression was suppressed by
about 50% relative to vehicle-treated animals in cortical bone of
PTH-treated 8-month-old wild-type and SOST Tg littermate mice
(see Fig. 1C). Moreover, human SOST expressed from the BAC
transgene in SOST Tg mice was significantly suppressed 4 hours
afterthelasthPTH(1–34)injection,comparablewithendogenous
mouse Sost (see Fig. 1D). The fairly mild osteopenia observed
underbaselineconditionsinSOSTTgmice(seeFig.1A,B)isinline
with the moderate overexpression of SOST under control of the
human SOST promoter and distant cis-regulatory elements
present in the BAC transgene reaching expression levels within
the physiologic range
(28) (see Fig. 1C, D).
Skeletal parameters of SOST Tg mice in response to
PTH treatment
Weanalyzedtheboneanabolicresponsesinthetibiaandlumbar
vertebrae of SOST Tg and wild-type littermate mice relative to
vehicle-treated animals using ex vivo whole-bone DXA measure-
ments. Intermittent PTH treatment significantly increased total
BMD in the tibia and lumbar spine of wild-type (þ17% and
þ14%, respectively) and SOST Tg (þ8% at both sites) mice.
However, PTH-induced bone gain was significantly attenuated
by about 50% in the appendicular and axial skeleton of SOST Tg
compared with wild-type littermate mice (Fig. 2A, B).
To characterize PTH-induced bone gain, we determined the
percent changes in cross-sectional total BMD and BMC in the
distal femur metaphysis relative to baseline using pQCT analyses
(seeFig.2C–E).Inwild-typemice,totalBMD(seeFig.2C)andtotal
BMC (see Fig. 2D) significantly increased by 20% and 26%,
respectively. In SOST Tg littermate mice, intermittent PTH
treatment also induced significant increases in total BMD
(þ13%; see Fig. 2C) and total BMC (þ16%; see Fig. 2D), but
the bone anabolic responses clearly were blunted compared
with the wild-type littermates.
Wethenanalyzedthe bonephenotypicchanges inthe cortical
and cancellous bone compartment of the distal femur
metaphysis by pQCT and high-resolution mCT. In wild-type
mice, high-dose intermittent PTH treatment significantly
increased cross-sectional cortical thickness by 28% relative to
baseline (see Fig. 2E, G). Cancellous BMD was significantly
augmented by 58% relative to vehicle-treated wild-type
littermates (see Fig. 2F, H). In SOST Tg mice, cortical thickness
wassignificantlyelevatedby15%relativetobaselineinresponse
tointermittentPTHtreatment(seeFig.2E,G),whereascancellous
BMD increased merely in a nonsignificant manner by 27%
compared with vehicle-treated transgenic littermates (see
Fig. 2F, H). Cancellous bone volume was significantly increased
by 73% in PTH-treated wild-type animals, whereas it was only
nonsignificantly increased by 29% in PTH-treated SOST Tg mice
(Table 1). Both trabecular number (þ12%) and thickness (þ11%)
were significantly increased in PTH-treated wild-type controls,
whereas increases were nonsignificant in SOST Tg mice (þ3%
and þ7%, respectively; see Table 1). Thus relative PTH-induced
bone anabolic responses were reduced by about 50% or more in
both bone compartments in SOST Tg compared with wild-type
littermate males
Bone formation and resorption parameters of SOST Tg
mice in response to PTH treatment
We next analyzed bone formation parameters in the cancellous
compartment of the distal femur metaphysis by dynamic bone
histomorphometry based on double-fluorochrome-marker
incorporation. In PTH-treated wild-type mice, mineralizing
surface and mineral apposition rate were significantly elevated
by 45% and 67% compared with vehicle-treated littermates,
respectively (Fig. 3B; see also Table 1). Mineralizing surface
(þ36%) and mineral apposition rate (þ54%) also were
significantly greater in PTH-treated SOST Tg relative to vehicle-
treated SOST Tg mice, but overall increases were smaller than in
PTH-treated wild-type mice, and the mineral apposition rate was
significantly lower in SOST Tg mice compared with wild-type
mice (see Table 1 and Fig. 3B). Consequently, while in wild-type
mice the bone formation rate was increased by 139% relative to
Fig. 2. PTH-induced bone gain is blunted in SOST Tg mice. Following 2
months of high-doseintermittent PTH treatment, overall BMDin thetibia
(A) and the lumbar vertebrae L1–4( B) was determined in wild-type and
SOSTTgmicebyexvivoDXAmeasurements.Percentagechangesrelative
tobaselinewerecalculatedforcross-sectionaltotalBMD(C),BMC(D),and
cortical thickness (E) in the distal femur metaphysis, as measured by in
vivo pQCT. Cancellous BMD in the distal femur metaphysis ( F) was
evaluated ex vivo by mCT, as illustrated by the 2D (G) and 3D mCT
reconstruction images (H). Data represent means SEM for vehicle-
(white bars) and PTH-treated (hatched bars) animals. Scale bars: (G)
0.5mm; (H) 0.25mm.
 ,Xp<.05;
  ,XXp<.01; unpaired Student’s t tests
for PTH- versus vehicle-treated mice of the same genotype (
 ,
  )o rSOST
Tg versus wild-type mice of the same treatment group (
X,
XX).
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significantly less in SOST Tg mice (þ111%; see Fig. 3A), further
demonstrating that elevated SOST expression levels cause a
reduction in the bone anabolic response to intermittent PTH
treatment. In contrast, the PTH-dependent increase in osteoclast
number was comparable between wild-type and SOST Tg mice,
and no significant differences were observed in vehicle- or PTH-
treated mice of either genotype (see Fig. 3C, D). Together these
data demonstrate that overexpression of SOST, while being PTH-
responsive, interferes with the full bone anabolic action of PTH in
vivo owing to the higher net Sost expression levels present in
SOST Tg mice following intermittent PTH treatment. To further
corroborate this finding, we next assessed the skeletal responses
to intermittent PTH treatment in homozygous Sost KO mice.
Skeletal parameters of Sost KO mice
Sost KO mice carry a targeted disruption of the 2-exon Sost
gene in which the majority of the Sost coding region was
replaced by an IRES-LacZ-neomycin/kanamycin resistance cas-
sette (Fig. 4A). Heterozygous Sost KO (Sost
þ/ ) mice were
interbred with generate homozygous Sost KO (Sost
 / ) and
wild-type offspring (see Fig. 4B), and their respective bone
phenotype was characterized by in vivo pQCT measurements
starting at 1 month of age during skeletal growth to skeletal
maturity at 4 months of age (see Fig. 4C, D). Consistent with Sost
encoding a potent bone formation inhibitor, homozygous Sost
KO mice develop a progressive high bone mass phenotype.
From 2 months of age onward, Sost
 /  male mice displayed
significantly higher cross-sectional total BMD (see Fig. 4C) and
elevated cortical thickness (see Fig. 4D) in the distal femur
metaphysis than their wild-type littermates.
To avoid a situation of saturated bone growth with bone filled
marrow cavities possibly present in older Sost
 /  mice, we
subjected 1.5-month-old Sost
 /  male mice and their wild-type
littermates to 2 months of treatment with daily injections of
100mg/kg hPTH(1–34). As expected, Sost expression was
completely eliminated in homozygous Sost KO mice in both
vehicle- and PTH-treated experimental groups, whereas wild-
type littermate mice showed a significant reduction in Sost
expression to about 60% of the level of vehicle-treated mice
4 hours after the final PTH application (see Fig. 4E).
Skeletal parameters of Sost KO mice in response to
PTH treatment
We determined the bone phenotypic responses to intermittent
PTH treatment using ex vivo whole-bone DXA analyses of the
tibia and lumbar vertebrae. As observed previously in skeletally
aging mice, 2 months of high-dose intermittent hPTH(1–34)
treatment significantly increased total BMD in the appendicular
and axial skeleton of skeletally growing wild-type mice by þ16%
in the tibia (Fig. 5A) and þ13% in the lumbar spine (see Fig. 5C)
compared with vehicle-treated littermates, respectively.
Total BMD values of the tibia and lumbar vertebrae of
vehicle- and PTH-treated Sost
 /  mice were significantly higher
than those of correspondingly treated wild-type mice. However,
Table 1. Bone Structure and Histomorphometric Indices in the Cancellous Bone Compartment of the Distal Femur Metaphysis of Wild-
Type and Sost Tg Mice After 2 Months of Intermittent PTH Treatment
Wild-type SOST Tg
Vehicle hPTH(1–34) Vehicle hPTH(1–34)
BV/TV (%) 8.4 0.5 14.6 0.9
   5.2 0.6
XX 6.7 0.7
XX
Tb.N (1/mm) 3.7 0.1 4.1 0.1
   3.4 0.1 3.5 0.1
XX
Tb.Th (mm) 51.7 1.3 57.2 2.0
  50.4 1.5 54.1 1.6
dLS/BS (%) 33.3 3.8 64.0 1.2
   41.6 2.7 65.6 2.0
  
MS/BS (%) 47.6 2.9 69.1 1.2
   51.7 2.4 70.6 1.9
  
MAR (mm/d) 0.41 0.01 0.69 0.02
   0.38 0.02 0.59 0.02
  ,XX
Data represent means SEM. BS¼bone surface; BV¼bone volume; dLS¼double-labeled surface; MAR¼mineral apposition rate; MS¼mineralizing
surface; Tb.N¼trabecular number; Tb.Th¼trabecular thickness; TV¼tissue volume.
 p<.05,
  p<.01 for PTH- versus vehicle-treated mice of the same genotype using unpaired Student’s t tests,
XXp<.01 for SOST Tg and wild-type mice with identical treatment using unpaired Student’s t tests.
Fig. 3. PTH-induced increase in bone formation rate is attenuated in
SOST Tg mice. (A) Bone formation rates were determined by dynamic
histomorphometry in the cancellous compartment of the distal femur
metaphysis of vehicle- (white bars) and PTH-treated (hatched bars) wild-
type and SOST Tg mice. (B) Representative images of fluorochrome-
marker-labeled trabecular bone surfaces. (C) Osteoclast number was
evaluated on TRAP-stained femoral sections, as illustrated by represen-
tative images of the cancellous compartment of the distal femur meta-
physis (D). Scale bars: (B) 0.5mm; (D)5mm. Data represent means SEM.
Xp<.05;
  p<0.01; unpaired Student’s t tests for PTH- versus vehicle-
treated mice of the same genotype (
  )o rSOST Tg versus wild-type mice
of the same treatment group (
X).
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 /  littermate mice did not
differ significantly in their total BMD at either skeletal site,
indicating a distinct blunting of PTH-induced bone anabolism in
Sost KO mice.
To study the effects of high-dose PTH treatment in Sost KO
mice in more detail, we next characterized the skeletal changes
in the femur by ex vivo consecutive pQCT measurements along
the femoral axis (see Fig. 5B, D, F). Femoral cross-sectional total
BMD was significantly increased in PTH- relative to vehicle-
treated wild-type mice, ranging from þ20% in the distal
metaphysis to about þ10% at the proximal end of the femoral
diaphysis (see Fig. 5B). Conversely, in Sost
 /  mice, intermittent
PTH treatment did not result in a significant gain in total BMD at
any femoral site analyzed relative to vehicle-treated littermate
mice. Likewise, at all evaluated femoral sites, cross-sectional total
BMC was significantly elevated in PTH- relative to vehicle-treated
wild-type mice, whereas in Sost
 /  mice, PTH treatment induced
only nonsignificant increases in total BMC compared with
vehicle-treated littermate mice (see Fig. 5D). Thus bone anabolic
responses to 2 months of high-dose PTH treatment are strongly
attenuated in skeletally growing Sost KO mice.
To determine whether PTH-induced bone anabolism was
equally blunted in both bone compartments of Sost
 /  mice, we
next determined the skeletal responses in femoral cancellous
BMD and cross-sectional cortical thickness using ex vivo high-
resolution mCT and multiple-slice pQCT analyses, respectively.
Cross-sectional cortical thickness was significantly increased by
about 15% to 40% in PTH- compared with vehicle-treated wild-
type mice depending on the respective position analyzed (see
Fig. 5F). In contrast, in Sost
 /  mice, no significant gain in cross-
sectional cortical thickness was detectable in PTH- relative to
vehicle-treated mice irrespective of the evaluated femoral site
(see Fig. 5F). Interestingly, we did not detect any net increase in
femoral cancellous BMD in response to intermittent PTH
treatment in either wild-type or Sost KO mice (see Fig. 5E, G,
H), most likely owing to the young age of the mice used in this
study in contrast to the aged wild-type and SOST Tg mice
described earlier (see Fig. 2F). Trabecular number actually was
significantly lower in either PTH-treated group ( 16% in wild-
type and  23%in Sost
 /  mice, respectively; Table 2). Trabecular
thickness, however, was significantly increased in PTH-treated
groups (þ36% in wild-type and þ31% in Sost
 /  mice,
respectively), suggesting that increased bone formation
occurred in response to PTH treatment. As a net outcome,
cancellous bone volume was unchanged in PTH-treated wild-
type animals and slightly decreased in PTH-treated Sost
 /  mice
( 15%; see Table 2).
Bone formation and resorption parameters of Sost KO
mice in response to PTH treatment
Using dynamic bone histomorphometry, we next analyzed bone
formation parameters in the cancellous bone compartment of
the distal femur metaphysis of Sost
 /  and wild-type littermate
mice in response to 2 months of high-dose hPTH(1–34)
treatment. Compared with wild-type mice, which showed a
significant increase in mineralizing surface by almost 50%
relative to vehicle-treated littermates, intermittent PTH treat-
ment did not significantly alter the percentage of mineralizing
surface in Sost
 /  mice relative to vehicle-treated Sost
 / 
littermates (see Table 2). In contrast, intermittent PTH treatment
caused a significant increase in mineral apposition rates in both
wild-type and Sost
 /  mice relative to vehicle-treated control
littermates (Fig. 6B; see also Table 2). However, PTH-dependent
stimulation of mineral apposition rate increase was reduced
by almost 40% in Sost
 /  mice (þ42% relative to vehicle-
treated KO mice) compared with wild-type littermates (þ68%
relative to vehicle-treated wild-type mice). As a consequence,
Fig. 4. Sost loss-of-function results in a progressive high bone mass
phenotype. (A) Genomic targeting scheme depicting the recombination
strategy for generatingthe targetedSost KO allele in which a 7.1-kb LacZ-
neomycin(Neo)/kanamycin(Kan) resistance selection cassette replaces
mostoftheSost codingregion,indicatedby theATGtranslationinitiation
and the TAG stop codon. Homology arms present in the targeting
construct are represented by gray arrows; the 2 exons of the Sost gene
are shown as black arrows. Flipase recognition target (FRT) sites for
optional removal of the selection cassette are depicted as black boxes
flanking the selection cassette. IRES¼internal ribosome entry site;
SA¼splice acceptor site. (B) Genomic DNA was extracted from tail
tips and used for genotyping of offspring obtained from heterozygous
(Sost
þ/ ) Sost KO breeding pairs to generate wild-type (WT), heterozy-
gous, and homozygous (Sost
 / ) Sost KO mice. Cross-sectional total BMD
(C) and cortical thickness (D) in the distal femur metaphysis of wild-
type (white data points) and Sost
 /  (filled data points) littermate male
mice were evaluated at monthly intervals starting at 1month of age
until skeletal maturity. (E) 4 hours after the final PTH or vehicle
application following 2 months of intermittent treatment with 100mg/
kg hPTH(1–34), the relative expression of Sost normalized to GAPDH,
with the corresponding DCt values indicated below the bars, was
determined by qPCR in cortical bone of the femur diaphysis. Data
represent means SEM. n.a.¼not applicable.
 p<.05,
  p<.01;
unpaired Student’s t tests for Sost
 /  versus wild-type mice (C, D)o r
PTH- versus vehicle-treated mice of the same genotype (E).
XXp<.01;
unpaired Student’s t tests for Sost
 /  versus wild-type mice of the same
treatment group (E).
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 / 
animals compared with wild-type littermate mice. While in wild-
type mice intermittent PTH treatment augmented the bone
formation rate to almost 150% of that of vehicle-treated wild-
typemice,PTHtreatmentcausedonlya33%increaseinthebone
formation rate of Sost
 /  mice relative to vehicle-treated Sost KO
mice (see Fig. 6A). Together these data demonstrate that bone
anabolic responses to intermittent PTH treatment are strongly
reduced in homozygous Sost KO mice. As in aged mice,
osteoclast number was significantly elevated in PTH- relative to
vehicle-treated wild-type littermates (þ37%; see Fig. 6C, D). In
PTH-treated Sost KO mice, osteoclast number increased only
nonsignificantly compared with vehicle-treated Sost KO mice
(þ28%), but no significant differences were detected between
genotypes of the same treatment group (see Fig. 6C, D).
Skeletal parameters of Sost KO mice in response to
different anabolic doses of PTH
Finally, to exclude the possibility that the observed blunting of
PTH-inducedboneanabolisminSost
 /  micewasmerelyaresult
Fig. 5. PTH-induced bone gain is blunted in Sost
 /  mice. OverallBMDin the tibia(A) andthe lumbarvertebrae L1–4( C) was determinedin wild-type and
Sost KO male mice ex vivo by DXA analyses following 2 months of high-dose intermittent PTH treatment. Femoral cross-sectional total BMD (B), BMC (D),
and cortical thickness ( F) were assessed by ex vivo pQCT measurements of five consecutive slices S1 to S5 distributed along the femoral axis at equal
distances from the distal metaphysis (S1) to the proximal end of the diaphysis (S5). Cancellous BMD in the distal femur metaphysis (E) was evaluated ex
vivo by mCT, as illustrated by the 2D (G) and 3D mCT reconstruction images (H). Scale bars: (G) 0.5mm; (H) 0.25mm. Data represent means SEM for
vehicle- (white bars) and PTH-treated (hatched bars) animals.
 ,Xp<.05;
  ,XXp<.01; unpaired Student’s t tests for PTH- versus vehicle-treated mice of the
same genotype (
 ,
  )o rSost
 /  versus wild-type mice of the same treatment group (
X,
XX).
184 Journal of Bone and Mineral Research KRAMER ET AL.of excessive stimulation of bone anabolic pathways triggered by
the high dailydose of100mg/kg hPTH(1–34)and bluntingwould
have not been detectable with lower doses of PTH, we repeated
the 2 months of intermittent PTH treatment. We applied daily
doses of 40 and 80mg/kg of hPTH(1–34), respectively, 2 doses
frequently used in mice to study PTH bone anabolic action in
vivo. The lower dose of 40mg/kg hPTH(1–34), while being
relatively moderate for mice, is still known to induce bone
anabolic responses in most mouse strains.
Similar to our previous observations with 100mg/kg hPTH(1–
34) daily dose, PTH-induced increase in cross-sectional total BMD
was strongly blunted in Sost
 /  mice independent of the PTH
dose and skeletal site analyzed. Cross-sectional total BMD in the
proximal tibia metaphysis was only nonsignificantly increased by
about 5% to 6% in PTH- relative to vehicle-treated Sost
 /  mice
(Fig. 7A). In contrast, wild-type mice revealed a significant 12%
and 19% increase in cross-sectional total BMD in responses to
2 months of intermittent treatment with daily doses of 40 or
80mg/kg hPTH(1–34), respectively (see Fig. 7A). Furthermore,
using multiple-slice pQCT measurements along the femoral axis,
we found only small, nonsignificant changes in cross-sectional
total BMD and BMC in Sost
 /  mice, whereas in wild-type mice
treated with daily doses of 40 or 80mg/kg hPTH(1–34), total BMD
waselevatedby6%to24%andtotalBMCby11%to26%relative
Table 2. Bone Structure and Histomorphometric Indices in the Cancellous Bone Compartment of the Distal Femur Metaphysis of
Homozygous Sost KO and Wild-Type Mice After 2 Months of Intermittent PTH Treatment
Wild-type Sost
 / 
Vehicle hPTH(1–34) Vehicle hPTH(1–34)
BV/TV (%) 13.1 1.0 13.0 2.2 30.2 3.7
XX 25.7 2.9
XX
Tb.N (1/mm) 5.1 0.1 4.3 0.3
  5.3 0.2 4.1 0.1
  
Tb.Th (mm) 44.6 1.1 60.8 2.4
   83.4 1.1
XX 109.6 4.3
  ,XX
dLS/BS (%) 28.4 5.1 61.4 2.2
   64.5 3.0
XX 63.5 3.7
MS/BS (%) 44.6 2.7 65.5 1.9
   70.8 2.0
XX 68.2 3.5
MAR (mm/d) 0.49 0.02 0.83 0.06
   0.79 0.07
XX 1.12 0.12
 
Data represent means SEM. BS¼bone surface; BV¼bone volume; dLS¼double labeled surface; MAR¼mineral apposition rate; MS¼mineralizing
surface; Tb.N¼trabecular number; Tb.Th¼trabecular thickness; TV¼tissue volume.
 p<.05,
  p<.01 for PTH- versus vehicle-treated mice of the same genotype using unpaired Student’s t tests,
XXp<.01 for Sost
 /  and wild-type mice with identical treatment using unpaired Student’s t tests.
Fig. 6. PTH-induced increase in bone formation rate is blunted in Sost
 /  mutant mice. (A) Bone formation rates were determined by dynamic
histomorphometry in the cancellous compartment of the distal femur metaphysis of vehicle- (white bars) and PTH-treated (hatched bars) wild-type and
Sost
 /  mice. (B) Representative images of fluorochrome-marker-labeled trabecular bone surfaces. (C) Osteoclast number was evaluated on TRAP-stained
femoralsections,asillustratedbyrepresentativeimagesofthecancellouscompartmentofthedistalfemurmetaphysis(D).Scalebars:(B)0.5mm;(D)5mm.
Data represent means SEM.
 ,Xp<.05;
  ,XXp<.01; unpaired Student’s t tests for PTH- versus vehicle-treated mice of the same genotype (
 ,
  )o rSost
 / 
versus wild-type mice of the same treatment group (
X,
XX).
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and femoral site analyzed (see Fig. 7C, D). As with 100mg/kg
hPTH(1–34) intermittent treatment, no net cancellous bone gain
was noticeable in either genotype compared with vehicle-
treated control mice (Table 3; see also Fig. 7B). Similar to the
previous study, we observed mainly PTH-induced cortical
bone gain by about 6% to 28% in wild-type mice depending
on the respective dose and femoral site analyzed, which was
blunted in Sost
 /  mice (see Fig. 7E). Consistent with the
previous study, trabecular number was significantly lower in all
PTH-treated groups (see Table 3). Trabecular thickness, however,
was significantly increased in PTH-treated groups [þ29% and
32% in wild-type mice and þ13% and þ23% in Sost
 /  mice
treated with 40 or 80mg/kg hPTH(1–34), respectively], suggest-
ing that increased bone formation occurred in response to PTH
treatment.
Discussion
Recently, we and others found that PTH suppresses transcription
of the osteocyte-specific bone formation inhibitor Sost.
(11,12)
Moreover, PTH treatment results in a decrease in the number of
osteocytes expressing sclerostin, the protein product of the Sost
gene.
(12,29) Here, we show that PTH-induced bone anabolism is
attenuated in mice with altered Sost expression levels.
In aging SOST Tg mice, PTH-induced cortical and cancellous
bone gain was attenuated in a comparable manner. These mice
are expected to express higher net levels of sclerostin protein
owing to the presence of the human SOST transgene. Therefore,
the observed blunting of bone apposition indicates that for
the full PTH bone anabolic response, Sost expression has to be
reduced to a threshold below the level present in SOST Tg mice
followingPTH application.Accordingly, onemightspeculatethat
theabsoluteSost expressionlevelattainedbyPTHsuppressionis
of more relevance than the relative difference in Sost expression
levels induced by PTH signaling. At the molecular level, PTH
application downregulated transgenic human SOST expression
by about 50%, similar to endogenous mouse Sost expression,
suggesting evolutionary conservation of PTH-induced suppres-
sion of SOST, an observation of putative importance concerning
the mechanism of action of intermittent PTH treatment applied
in the clinic. It is conceivable that PTH-induced suppression of
SOST is mediated in part via the distant downstream bone
enhancer also present in the SOST BAC transgene of SOST Tg
mice. Consistently, we recently identified a conserved myocyte
enhancer factor 2 (MEF2) response element in the distant SOST
bone enhancer that is required for enhancer activity and is
sufficient to mediate PTH-mediated suppression of SOST
enhancer activity in vitro.
(30) In this respect, it will be interesting
to address in future studies the relevance of the distant SOST
bone enhancer and the role of MEF2 transcription factors for
PTH-induced bone anabolism in vivo.
While PTH-induced cancellous bone volume gain was clearly
blunted in SOST Tg mice, similar to the observed blunting in the
cortical bone compartment, PTH-dependent increase in cancel-
lous bone formation rate was comparatively less strongly
attenuated. This could be explained by partly altered kinetics of
induction of PTH-dependent anabolism in wild-type versus SOST
Tg mice and/or by the reduced cancellous bone template
present in osteopenic SOST Tg mice at baseline. Along this line, it
has been suggested that PTH treatment is less effective at
skeletal sites with a lower amount of preexisting trabecular
bone.
(31) Moreover, we cannot exclude that Sost inhibits not only
bone anabolic pathways acting downstream of PTH but also
affects parallel bone anabolic pathways independent of PTH
action. However, bone formation rates did not differ between
vehicle-treated wild-type and SOST Tg mice, whereas they were
attenuated in PTH-treated SOST Tg mice compared with treated
Fig. 7. PTH-induced bone gain is blunted in Sost
 /  mice irrespective of
the applied PTH dose. (A) Cross-sectional total BMD in the proximal tibia
metaphysis was determined by in vivo pQCT analyses in wild-type and
Sost
 /  male mice after 2 months of intermittent treatment with daily
injections of vehicle (white bars)o r4 0( fine hatched bars)o r8 0 mg/kg
hPTH(1–34) (bold hatched bars). (B) Cancellous BMD was evaluated in the
distal femur metaphysis by ex vivo mCT. (C) Femoral cross-sectional total
BMD, total BMC (D), and cortical thickness (E) were evaluated by ex vivo
pQCT analyses of five consecutive slices S1 to S5 distributed along the
femoral axis at equal distances from the distal metaphysis (S1) to the
proximal end of the diaphysis (S5). Data represent means SEM.
 ,Xp<.05;
  ,XXp<.01; unpaired Student’s t tests for PTH- versus vehi-
cle-treated mice of the same genotype (
 ,
  )o rSost
 /  versus wild-type
mice of the same treatment group (
X,
XX).
186 Journal of Bone and Mineral Research KRAMER ET AL.wild-type mice. Hence it seems unlikely that the observed
blunting of PTH-induced bone gain in SOST Tg mice was merely
the result of an independent superimposed negative effect on
parallel bone anabolic pathways. To further consolidate this
interpretation, we analyzed PTH-induced bone anabolism in Sost
KO mice lacking Sost expression constitutively. If bone anabolic
pathways inhibited by Sost action differed from bone anabolic
pathways activated by intermittent PTH treatment, we would
have expected to observe additive effects of PTH-induced bone
anabolism and Sost loss-of-function-dependent bone gain.
Instead, we found that PTH-induced bone gain was severely
impaired in the skeleton of growing homozygous Sost KO mice,
providing further evidence that Sost suppression contributes to
PTH-induced bone gain.
Morphologically, PTH bone anabolic action appears to rely in
part on the reactivation of quiescent lining cells into bone-
forming cells that contribute to PTH-induced increase in
mineralizing bone surface.
(7,32) In addition, PTH-induced expan-
sion of mineralizing bone surface is thought to result from
increases in osteoblast number via enhanced osteoblastic
precursor proliferation and/or differentiation,
(5,6,10) as well as
reduced osteoblast apoptosis.
(8,9) In wild-type as well as in SOST
Tg mice, the relative mineralizing surface increased to 65% to
70% in response to 2 months of high-dose intermittent PTH
treatment. This corresponds to the level of mineralizing bone
surface present in vehicle-treated homozygous Sost KO mice,
which did not further expand in PTH-treated Sost KO littermates,
raising the issue of whether an inherent biologic limit exists in
vivo that restricts the extent of active bone forming surface.
Presently, wecannot fully exclude that the severeblunting ofthe
PTH-induced increase in mineralizing surface observed in Sost
KO miceispartlyduetosuch aputative inherentsaturation point
reached in homozygous Sost KO animals. However, the observed
blunting of osteoblastic mineral apposition rate in PTH-treated
SOST Tg mice cannot be explained by such a hypothetical
mechanism. Moreover, while being attenuated, intermittent PTH
treatment still increased mineral apposition rate in Sost KO mice,
indicating that bone formation had not reached a terminal
saturation point in Sost KO mice. Importantly, PTH-induced bone
gainalsowasstronglybluntedinSostKOmicetreatedwithlower
doses of hPTH(1–34), excluding that the observed reduction of
PTH-induced bone gain in homozygous Sost KO mice was only
due to excessive stimulation of bone anabolic pathways
triggered by the high PTH dose. Finally, since Sost KO mice
displayanelevatedmatrixapposition rateandmineralizingbone
surface, it appears that Sost inhibits osteoblastic bone matrix
deposition as well as negatively regulates osteoblast recruitment
and/or survival consistent with previous findings.
(21,33,34) The
present study suggests that both aspects of Sost action are of
relevance for PTH-induced bone anabolism because either was
affected by altered Sost gene dosage.
Unexpectedly, we did not observe any net increase in femoral
cancellous BMD in growing wild-type and Sost KO mice
subjected to intermittent PTH treatment in two independent
studies. Nonetheless, trabecular thickness and cancellous bone
formation rates increased in a manner comparable with the
elevated cortical thickness and total BMD gain observed in wild-
type mice at all skeletal sites. Thus it appears that intermittent
PTH treatment stimulated bone formation responses in both
bone compartments to a similar extent but failed to induce
sustainable cancellous bone gain. Failure to achieve net
cancellous bone gain was related to a decrease in trabecular
number in PTH-treated animals of either genotype. Moreover,
osteoclast number increased significantly in PTH-treated wild-
type andnonsignificantly inPTH-treated SostKO mice, indicating
that the rarefied trabecular number was the consequence of
PTH-stimulated enhanced bone resorption. Interestingly, while
PTH-induced percentage increase in osteoclast number was
similar or even slightly higher in aged wild-type and SOST Tg
mice at the end of the treatment period, this did not
interfere with overall cancellous bone gain in these animals.
Thus it appears that net cancellous bone gain induced by
intermittentPTHtreatmentisregulatedbyadditionalfactorsthat
might vary with age. Indeed, the number of bone resorbing
osteoclasts was approximately doubled in young wild-type and
Sost deficient animals compared with aged wild-type and SOST
Tg mice irrespective of treatment. Another aspect that might
contribute to these variations is the difference in genetic
background. This notionissupported bythevariabilityinskeletal
responses to intermittent PTH treatment observed in different
mouse strains.
(31,35) Since net cancellous bone gain was
undetectable in PTH-treated mice of either genotype and bone
resorption parameters were comparable between genotypes of
the same treatment group, Sost does not appear to have a major
impact on PTH-induced bone resorption. Similarly, we did not
detect any significant differences in osteoclast number compar-
ing wild-type and SOST Tg mice or the relative PTH-triggered
increases thereof, consistent with previous findings implicating
Sost in the regulation of bone formation but not bone
resorption.
(20,21)
Table 3. BoneStructure Indices inthe Cancellous BoneCompartment oftheDistal Femur Metaphysis ofHomozygous SostKO andWild-
Type Mice After 2 Months of Intermittent PTH Treatment With Different PTH Doses
Wild-type Sost
 / 
Vehicle 40mg/kg hPTH(1–34) 80mg/kg hPTH(1–34) Vehicle 40mg/kg hPTH(1–34) 80mg/kg hPTH(1–34)




Tb.N (1/mm) 5.2 0.1 4.0 0.1
   4.2 0.1
   6.1 0.3
X 5.0 0.5 4.4 0.2
  
Tb.Th (mm) 46.8 1.4 60.2 2.5
   61.9 3.2
   84.3 2.4
XX 95.3 3.5
 ,XX 104.4 1.9
  ,XX
Data represent means SEM. BV¼bone volume; Tb.N¼trabecular number; Tb.Th¼trabecular thickness; TV¼tissue volume.
 p<.05,
  p<.01 for PTH-versus vehicle-treated mice of the same genotype using unpaired Student’s t tests,
Xp<.5,
XXp<.01 for Sost
 /  and wild-type mice with identical treatment using unpaired Student’s t tests.
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treatment, continuous PTH application is mostly bone catabolic
owing to increased bone turnover, with elevated osteoclastic
bone resorption exceeding the PTH-induced osteoblastic bone
formation increase,
(36,37) whereas osteocytic Sost expression is
suppressed in both situations.
(12) Recently, the role of PTH
signaling in osteocytes was addressed in mice overexpressing a
constitutively active PTH1R variant selectively in osteocytes,
mimicking part of the effects triggered by continuous systemic
PTH exposure in vivo.
(13) These transgenic mice displayed a
bone-overgrowth phenotype that was characterized by elevated
bone turnover, decreased Sost expression, and increased Wnt
signaling. In adult bone, Sost-encoded sclerostin is speculated to
function as a secreted inhibitor of b-catenin-dependent
canonical Wnt signaling by binding to Lrp5 and Lrp6 Wnt
coreceptors, preventing their association with the Wnt-Frizzled
receptor complex.
(38,39) Given the importance of b-catenin-
dependent canonical Wnt signaling for bone homeostasis,
(40–43)
the role of Wnt signaling in PTH-induced bone anabolism has
been addressed previously in vivo.
(44–46) Similar to the findings
presented here for Sost KO mice, deletion of the Wnt signaling
antagonist secreted frizzled-related protein 1 attenuates PTH-
induced bone anabolism in vivo,
(46) suggesting that activation of
Wnt signaling contributes to PTH bone anabolic action. In
addition, accumulating in vitro and in vivo evidence suggests a
possible role for direct interaction of PTH1R and canonical Wnt
signaling pathways.
(47–50) Together, these findings point to
potential mechanisms as to why PTH-induced suppression of
Sost might be required for the full bone anabolic action of PTH in
vivo.
In summary, we have shown in the present study that the in
vivo bone anabolic action of intermittent PTH treatment is
attenuated in Sost gain- and loss-of-function mouse models.
Thus PTH-mediated suppression of the PTH downstream target
Sost appears to contribute to PTH-induced bone gain in vivo.
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